Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group
New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce disease recurrence and treatment-related morbidity. The Children’s Oncology Group Phase III AAML1031 trial tested whether the addition of bortezomib to standard chemotherapy improves survival in pediatric pati...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Ferrata Storti Foundation
2020-07-01
|
| Serier: | Haematologica |
| Online adgang: | https://haematologica.org/article/view/9939 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
